New hope for eye cancer: targeted drug combo shows promise in early trial
NCT ID NCT07247383
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests a targeted cancer drug called orelabrutinib combined with either low-dose radiation or another drug (rituximab) in 39 people with a rare eye lymphoma (ocular adnexal MALT lymphoma). The goal is to see how well the combination shrinks tumors and how safe it is. Participants have early-stage disease and have not had prior treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Orelabrutinib (a targeted cancer drug) plus either low-dose radiation or rituximab (another cancer drug)
What this could lead to
If successful, this could offer a new, less toxic treatment option for a rare eye lymphoma, potentially improving tumor control without harsh side effects.
What could go wrong
This is a small, early-phase trial (39 people) with no control group, so results may not apply broadly. The combination may cause side effects or fail to shrink tumors in some patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA (MZL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
2ndAffiliated Hospital, School of Medicine, Zhejiang University, China
Hangzhou, Zhejiang, 310000, China